

ADVANCING IMMUNO-GENE THERAPY
ACROSS DISEASES

INTERNATIONAL CONFERENCE ON LYMPHOCYTE ENGINEERING 2018

13-15 SEPTEMBER
MADRID, SPAIN

Dear Colleagues,

It is our pleasure to invite you to the First International Conference on Lymphocyte Engineering (ICLE 2018), set to take place in Madrid, on 13-15 September 2018.

Great strides have been made in recent years in the engineering of lymphocytes for the treatment of cancer, autoimmune diseases, pathogenic diseases and primary immune deficiencies. Combining gene therapy, cell therapy and immune therapy, the emerging field of lymphocyte engineering employs cutting edge technologies of viral and non-viral vectorology, genome editing and protein design as well as advanced clinical protocols for cell harvest, expansion and re-infusion. With groundbreaking clinical success leading to FDA approved products and with vibrant, exponentially growing research, lymphocyte engineering is the wave of the future.

Still, the challenges are formidable and the stakes are high. Realizing the full promise of lymphocyte engineering will require the combined efforts of a dedicated community. ICLE 2018 will facilitate the sharing of data and ideas, promote collaborations, and address common challenges to advance clinical translation. It will provide an effective environment for active learning, discussions of real-world case studies and for networking between like-minded peers.

Whether you are a scientist, clinical researcher, part of a start-up or an established industry company, ICLE 2018 is your opportunity to network and discuss immuno-gene therapy with those as excited and passionate about this innovative treatment modality.

See you in Madrid!



On behalf of the Advisory Board,

Adi Barzel

Conference Chair

President of the Israeli Society for Gene and Cell Therapy (ISGCT)

Senior Lecturer at Tel-Aviv University



ADVISORY BOARD

Malcolm Brenner

Center for Cell and Gene Therapy,
Texas Children's Hospital, USA

Paula Cannon

University of Southern California,
USA

Cyrille Cohen

Bar-Ilan University,
Israel

Zelig Eshhar

The Weizmann Institute of Science and
Sourasky Medical Center, Israel

Dinorah Friedmann-Morvinski

Tel Aviv University,
Israel

Stephen Gottschalk

St. Jude Children's
Research Hospital, USA

Gideon Gross

Immunology Laboratory, MIGAL Galilee
Research Institute Ltd., Israel

Ayal Hendel

Principal Investigator at Bar-Ilan
University, Israel

Aya Jakobovits

Adicet Bio, Inc.,
USA

Carl June

Perelman School of Medicine,
University of Pennsylvania, USA

Bruce Levine

University of Pennsylvania,
USA

Marcela Maus

Massachusetts General Hospital,
USA

Dan Peer

Tel Aviv University Cancer Biology
Research Center, Israel

Matthew Porteus

Stanford University,
USA

Daniel Powell

University of Pennsylvania,
USA

Barbara Savoldo

University of North Carolina

KEYNOTE SPEAKERS



MALCOLM BRENNER

Center for Cell and Gene Therapy,
Texas Children`s Hospital
USA



CARL JUNE

Perelman School of Medicine,
University of Pennsylvania
USA



ZELIG ESHHAR

The Weizmann Institute of Science and
Sourasky Medical Center
Israel

WHY ATTEND

- Participate in the only event that merges all the exciting breakthroughs under one conference - gene therapy, cell therapy, genome engineering, and immunotherapy.
- Gain access to quality networking with colleagues advancing related knowledge across diseases.
- Meet the thought leaders, who will share invaluable insights on CAR-T Cell and other lymphocyte engineering therapies.
- Present your research, clinical findings, therapies and pipeline to a focused international audience.
- Become part of the only community across industry and academia dedicated to lymphocyte engineering.



PRESENT ALONGSIDE THE EXPERTS

SUBMIT YOUR ABSTRACT

Participants interested in presenting an Oral or Poster presentation are invited to submit an abstract. Companies are invited to highlight their clinical trials or pipeline.

- Genome editing for allogeneic ACT
- Safety switches & controlled expression
- Hematological malignancies
- Engineering HSC, NK, NKT and $\gamma\delta$ T cells
- Target & receptor discovery
- Solid tumours
- HIV
- Receptor and vector design
- Non-viral vectors and transposons
- Other

DEADLINE: WEDNESDAY, 23 MAY 2018
TO SUBMIT AN ABSTRACT, CLICK HERE

THURSDAY, 13 SEPTEMBER 2018

08:00-11:00 **REGISTRATION**

11:00-11:30 **OPENING ADDRESS**

11:30-13:00 **SESSION 1: CLINICAL UPDATES IN HEMATOLOGICAL MALIGNANCIES**



ACCELERATING THE EVOLUTION OF CELL THERAPY

Malcolm Brenner, Founding Director at the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, USA



Michal Besser, Head of Laboratory, Ella Lemelbaum Institute for Immuno Oncology, Sheba Medical Center, Israel



CAR-T THERAPY FOR B CELL MALIGNANCIES

Jenifer Brogdon, Director, Exploratory Immuno-Oncology, Novartis Institutes for Biomedical Research, USA



XCELLERATE - NEXTGEN MANUFACTURING PLATFORM FOR IMPROVED CAR T CELLS

Lothar Germeroth, SVP Juno Therapeutics, Inc., USA

13:00-14:30 Lunch, Networking & Exhibition

14:30-16:30 **SESSION 2: FIGHTING SOLID TUMORS WITH ENGINEERED LYMPHOCYTES**



TARGETING OF MULTIPLE TUMORS AND VIRAL-INFECTED CELLS USING T-CELLS ENGINEERED TO EXPRESS NCR-BASED CHIMERIC RECEPTORS

Cyrille Cohen, Associate Professor at Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Israel





T CELL RECEPTOR GENE THERAPY

Thomas Blankenstein, Head of Molecular Immunology and Gene Therapy at Max-Delbrück-Center for Molecular Medicine (MDC), Germany



ENGINEERING T CELLS FOR THE IMMUNOTHERAPY OF SOLID TUMORS

Stephen Gottschalk, Chair of the Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, USA



CAR T CELLS IN GLIOBLASTOMA AND OTHER SOLID TUMORS

Marcela Maus, Director, Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Assistant Professor of Medicine, Harvard Medical School, Associate Member, Broad Institute of MIT and Harvard, USA


16:30-17:30 Coffee Break, Poster Viewing, Networking & Exhibition

17:30- 19:30 SESSION 3: NON VIRAL VECTORS AND TRANSPOSONS



ENGINEERING LYMPHOCYTES WITH RNAi NANOMEDICINES

Dan Peer, Director, Tel Aviv University Cancer Biology Research Center, Director, Laboratory of Precision NanoMedicine, Dept. of Cell Research & Immunology, and Dept. of Materials Science & Engineering, Director, Leona M. and Harry B. Helmsley Nanotechnology Research Fund, Israel



NEW TARGETS AND TECHNOLOGIES FOR CAR-T

Michael Hudecek, Leading Hudecek Lab at Hospital of the University of Würzburg, Germany



ENGINEERING T CELLS FROM BENCH TO BED TO BOARDROOM

Laurence Cooper, Visiting Scientist at University of Texas MD Anderson Cancer Center Houston, Texas, Visiting Scientist, Department of Pediatrics Chief Executive Officer, ZIOPHARM Oncology, USA

19:30 NETWORKING WELCOME RECEPTION

FRIDAY, 14 SEPTEMBER 2018

08:30-10:30 **SESSION 4: GENOME EDITING AND ALLOGENEIC ACT**



GENE EDITED ALLOGENEIC T CELL THERAPIES

Waseem Qasim, Professor of Cell and Gene Therapy, Institute of Child Health, UCL, Consultant in Pediatric Immunology, Reader in Cell and Gene Therapy at Great Ormond Street Hospital for Children NHS Trust, UK



Ayal Hendel, Principal Investigator at Bar-Ilan University, Israel



CAR T CELL THERAPY: THE CD19 PARADIGM

Xiuyan Wang, Assistant Director, Michael G.Harris Cell Therapy and Cell Engineering Facility; Associate Laboratory Member, Department of Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, USA



GENE EDITED UNIVERSAL OFF-THE-SHELF IMMUNOTHERAPIES: A FUTURE-DEFINING SHIFT IN SIMPLICITY, AVAILABILITY, AND COST-EFFECTIVENESS

André Choulika, Chairman & CEO of Cellectis Inc., USA

10:30-11:00 Coffee Break, Poster Viewing, Networking & Exhibition

11:00-13:00 **SESSION 5: NEW HORIZONS FOR LYMPHOCYTE AND HSC ENGINEERING**



HIGHLY EFFICIENT EDITING OF PRIMARY HUMAN BLOOD CELLS BY HOMOLOGOUS RECOMBINATION

Matthew Porteus, Associate Professor of Pediatrics (Stem cell transplantation) at Stanford University, USA



ENGINEERING REGULATORY T-CELL THERAPEUTICS

Andrew Scharenberg, Professor, Department of Pediatrics, University of Washington, Attending Physician, Seattle Children's Hospital, Chief Scientific Officer, Casebia Therapeutics, USA

13:00-14:30 Lunch, Networking & Exhibition

14:30-16:30 **SESSION 6: ENGINEERING LYMPHOCYTES TO CLEAR INFECTIONS****ENGINEERING RESISTANCE AND PERSISTENCE- T CELLS FIGHT BACK AGAINST HIV**

Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy
 Founding Director, Clinical Cell and Vaccine Production Facility Center for Cellular
 Immunotherapies Deputy Director – Technology Innovation and Assessment
 Department of Pathology and Laboratory Medicine Perelman School of Medicine,
 Abramson Cancer Center, University of Pennsylvania, USA

**ENGINEERING HSC AND LYMPHOCYTES TO SUPPRESS HIV**

Paula Cannon, Professor of Molecular Microbiology and Immunobiology at Keck
 School of Medicine of University of Southern California, USA

**ENGINEERING ANTIVIRAL CAR T-CELL IMMUNITY THROUGH HEMATOPOIETIC STEM/PROGENITOR CELLS**

Scott Kitchen, Director, UCLA Humanized Mouse Core Laboratory, Division of
 Hematology/Oncology, The David Geffen School of Medicine, UCLA, USA

16:30-17:30 Coffee Break, Poster Viewing, Networking & Exhibition

17:30-19:30 **SESSION 7: OPTIMIZING RECEPTOR AND VECTOR DESIGN****FROM A CANCER CAUSING VIRUS TO A SAFER TOOL FOR GENE THERAPY AND IMMUNOTHERAPEUTICS**

Axel Schambach, Director, Institute for Experimental Hematology, Hannover
 Medical School, Germany

**RECEPTOR-TARGETED VIRAL VECTORS IN IMMUNOTHERAPY**

Christian Buchholz, Head of Molecular Biotechnology and Gene Therapy
 Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Germany

**CLINICAL TRIALS USING CD19-TARGETING, THIRD GENERATION CAR T CELLS WITH CD28 AND 4-1BB SIGNALING DOMAINS IN PATIENTS WITH B CELL MALIGNANCY**

Angelica Loskog, Professor of Immunotherapy (adjunct) Department of
 Immunology, Genetics and Pathology, Uppsala University, Sweden

SATURDAY, 15 SEPTEMBER 2018

08:30-10:30 **SESSION 8: SAFETY SWITCHES & CONTROLLED EXPRESSION**



STRATEGIES FOR QUANTITATIVE CONTROL OF REDIRECTED GENE-ENGINEERED T CELL ACTIVITY

Daniel Powell, Associate Professor of Pathology and Laboratory Medicine, Associate Professor of Obstetrics and Gynecology, University of Pennsylvania Perelman School of Medicine, USA



USING mRNA FOR IMPROVING T CELL PERFORMANCE IN ADOPTIVE CELL THERAPY

Gideon Gross, Head of Immunology Laboratory, MIGAL Galilee Research Institute Ltd., Senior faculty member at Tel-Hai College in the Upper Galilee, Israel



ISOLATION AND IDENTIFICATION OF OPTIMAL T CELLS AND RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY

Dirk Busch, Director at the Institute for Med. Microbiology, Immunology and Hygiene Technical University of Munich, Germany

10:30-11:00 Coffee Break, Networking & Exhibition

11:00-13:00 **SESSION 9: NEW TARGETS AND NEW RECEPTORS**



DESIGNER T CELLS FOR IMMUNOTHERAPY OF CANCER

Wolfgang Uckert, Head of Department on Molecular Cell Biology and Gene Therapy at Max-Delbrück-Center for Molecular Medicine (MDC), Germany



P32, A NOVEL TARGET OF CAR T-CELL THERAPY FOR GLIOMAS

Dinora Friedmann-Morvinski, Senior Lecturer at Tel Aviv University, Israel



DAYS OF THUNDER: CHALLENGES WHEN SEEKING NEW CARs

Barbara Savoldo, Associate Director for the UC Lineberger, Immunotherapy Program at UNC Chapel Hill, NC Lineberger Comprehensive Cancer Center Professor in Immunology, Virology and Pediatrics Hem-Oncology, University of North Carolina at Chapel Hill, USA



13:00-14:30 Lunch, Networking & Exhibition

14:30-16:30 **SESSION 10: CONCLUDING KEYNOTE LECTURES**



KEYNOTE LECTURE

Carl June, Director, Center for Cellular Immunotherapies, Director, Parker Institute Cancer Immunotherapy, Pathology and Laboratory Medicine department
University of Pennsylvania, USA



Zelig Eshhar, The Marshall and Renette Erzalow Professor of chemical and Cellular Immunology, Weizmann Institute of Science, Israel



WHAT'S NEXT? FROM PERSONALIZED TO "OFF THE SHELF" CARs

Anat Globerson Levin, Director and Senior Scientist, Immunology Research Lab, Tel Aviv Sourasky Medical Center, Israel

PANEL DISCUSSION: LYMPHOCYTE ENGINEERING - WHAT'S NEXT?

16:30 **CLOSING CEREMONY**

SUPPORT OPPORTUNITIES

Choose your way of raising brand awareness and spotlighting your research and technologies by supporting this outstanding conference:

- Participate in the Programme
- Commit a Scientific Grant
- Be the centrepiece of the Exhibition
- Join the Start-up Industry Hub
- Submit an Industry Abstract and Present it at the Research Theatre
- Advertise
- Send delegates

To customize a package to your needs, please contact Nelly Dimitrova at ndimitrova@kenes.com, tel.: +359 2 419 8397